Differences in approaches to managing patients with multiple myeloma vs amyloidosis

Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, Cleveland Clinic, Cleveland, OH, comments on the differences in management between patients with multiple myeloma and patients with amyloidosis, explaining that patients with amyloidosis experience different toxicities to anti-myeloma therapies and may require dose adjustments. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.